View source for Table of frequent aberrant markers in AML

----
<div style="width: 200px">
{| class="wikitable" style="border-left:solid 5px green;border-right:solid 5px green;border-top:solid 5px black;border-bottom:solid 5px black; font-size:90%; color:navy"
| colspan="1"''|[[The flow cytometric diagnosis of AML|Return to previous page]]''
|}
</div>

----

<div style="width: 100%">
{| class="wikitable" style="border-style: solid; border-width: 5px; color:black"
|colspan="1" style = "font-size:90%; color:black; background: #bcd4e6"|'''What s the importance of abberent marker expression?'''
|}
</div>
The key point is that AML will frequently express immunological markers not typically associated with myeloid lineage. This is aknowledged in diagnostic criteria and providing diagnostic criteria are applied they do not require a change in diagnosis.</br>The most frequent "abberencies" observed in AML are</br>
</br>(1) The expression of CD7 by nearly half of cases</br>(2) The expression of CD19 (often associated with particular AML subtypes)

-----
<div style="width: 100%">
{| class="wikitable" style="border-style: solid; border-width: 5px; color:black"
|colspan="1" style = "font-size:90%; color:black; background: #bcd4e6"|'''Do abberent markers have patterns?'''
|}
</div>
Markers associated with lymphoid maturation that may also be expressed by the lineage maturation, particularly monocytic lineage
CD2 CD4, 36 38 MONOCYTIC 5%

Frequent abberant markers in AML that are often associated with genetic/cytogenetic subtype: 
CD19 30% CBF RUNX1, BCRABL 
CD56 CBF RUNX1
NPM1 OFTEN LACK CD34

----